dc.contributor.author | Sohretoglu, Didem | |
dc.contributor.author | Huang, Shile | |
dc.date.accessioned | 2019-12-16T10:09:52Z | |
dc.date.available | 2019-12-16T10:09:52Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 1871-5206 | |
dc.identifier.uri | https://doi.org/10.2174/1871520617666171113121246 | |
dc.identifier.uri | http://hdl.handle.net/11655/19987 | |
dc.description.abstract | The mushroom Ganoderma lucidum (G. lucidum) has been used for centuries in Asian countries to treat various diseases and to promote health and longevity. Clinical studies have shown beneficial effects of G. lucidum as an alternative adjuvant therapy in cancer patients without obvious toxicity. G. lucidum polysaccharides (GLP) is the main bioactive component in the water soluble extracts of this mushroom. Evidence from in vitro and in vivo studies has demonstrated that GLP possesses potential anticancer activity through immunomodulatory, anti-proliferative, pro-apoptotic, anti-metastatic and anti-angiogenic effects. Here, we briefly summarize these anticancer effects of GLP and the underlying mechanisms. | |
dc.language.iso | en | |
dc.publisher | Bentham Science Publ Ltd | |
dc.relation.isversionof | 10.2174/1871520617666171113121246 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Oncology | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Ganoderma Lucidum Polysaccharides As An Anti-Cancer Agent | |
dc.type | info:eu-repo/semantics/review | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Anti-Cancer Agents In Medicinal Chemistry | |
dc.contributor.department | Farmakognozi | |
dc.identifier.volume | 18 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 667 | |
dc.identifier.endpage | 674 | |
dc.description.index | WoS | |